Table 2.
Phenotype | Total (Range) | Tumor (Range) * | Stroma (Range) * | p * |
---|---|---|---|---|
Total CK+ | 995.08 (42–610.94) | 1707.04 (121.45–6107.18) | - | - |
Total CD68+ | 62.24 (1.83–451.88) | 74.20 (1.24–396.92) | 54.75 (0.00–645.24) | 0.938 |
(M1) CD68+MRP8-14+CD163negCD206negArg-1neg | 0.00 (0.00–21.53) | 0.00 (0.00–37.22) | 0.00 (0.00–16.94) | 0.254 |
(M1) CD68+CD86+CD163negCD206negArg-1neg | 0.00 (0.00–20.04) | 0.00 (0.00–20.68) | 0.00 (0.00–70.93) | 0.765 |
(M1) CD68+CD86+MRP8-14+CD163negCD206negArg-1neg | 0.00 (0.00–0.94) | 0.00 (0.00–4.14) | 0.00 (0.00–0.00) | 0.605 |
(M2) CD68+CD163+MRP8-14negCD86neg | 28.33 (0.00–215.25) | 29.09 (0.00–153.37) | 18.12 (0.00–354.64) | 0.657 |
(M2) CD68+CD206+MRP8-14negCD86neg | 1.98 (0.00–69.97) | 1.58 (0.00–46.28) | 1.14 (0.00–191.07) | 0.615 |
(M2) CD68+CD163+CD206+MRP8-14negCD86neg | 1.55 (0.00–68.94) | 1.22 (0.00–44.92) | 1.08 (0.00–155.97) | 0.574 |
(M2a) CD68+CD163+Arg-1+MRP8-14negCD86neg | 0.00 (0.00–15.20) | 0.00 (0.00–16.94) | 0.00 (0.00–12.46) | 0.010 |
(M2a) CD68+CD206+Arg-1+MRP8-14negCD86neg | 0.00 (0.00–2.26) | 0.00 (0.00–2.65) | 0.00 (0.00–1.66) | 0.089 |
(M2a) CD68+CD163+CD206+Arg-1+MRP8-14negCD86neg | 0.00 (0.00–67.92) | 0.00 (0.00–44.01) | 0.00 (0.00–155.97) | 0.278 |
(M2b) CD68+CD86+MRP8-14neg | 0.97 (0.00–23.45) | 0.48 (0.00–20.68) | 0.00 (0.00–82.76) | 0.585 |
(M2c) CD68+CD163+Arg-1negMRP8-14negCD86neg | 27.89 (0.00–214.71) | 28.31 (0.00–153.37) | 18.12 (0.00–354.64) | 0.951 |
(M2c) CD68+CD206+Arg-1negMRP8-14negCD86neg | 1.77 (0.00–69.26) | 1.56 (0.00–45.37) | 1.03 (0.00–191.07) | 0.626 |
(M2c) CD68+CD163+CD206+Arg-1negMRP8-14negCD86neg | 0.00 (0.00–43.69) | 0.00 (0.00–6.28) | 0.00 (0.00–151.81) | 0.904 |
CK+PD-L1+ | 0.00 (0.00–1.55) | 0.00 (0.00–10.05) | - | - |
CD68+PD-L1+ | 0.00 (0.00–2.48) | 0.00 (0.00–0.00) | 0.00 (0.00–0.48) | 0.608 |
Note: (M), macrophages; * p, correlation between tumor and stroma compartment using Kruskal–Wallis test.